| |  Online-Ressource |
|---|
| Verfasst von: | Jank, Paul [VerfasserIn]  |
|---|
| | Karn, Thomas [VerfasserIn] |
|---|
| | van Mackelenbergh, Marion [VerfasserIn] |
|---|
| | Lindner, Judith [VerfasserIn] |
|---|
| | Treue, Denise [VerfasserIn] |
|---|
| | Huober, Jens [VerfasserIn] |
|---|
| | Engels, Knut [VerfasserIn] |
|---|
| | Solbach, Christine [VerfasserIn] |
|---|
| | Diebold, Kurt [VerfasserIn] |
|---|
| | Marmé, Frederik [VerfasserIn] |
|---|
| | Müller, Volkmar [VerfasserIn] |
|---|
| | Schneeweiss, Andreas [VerfasserIn] |
|---|
| | Sinn, Peter [VerfasserIn] |
|---|
| | Fehm, Tanja [VerfasserIn] |
|---|
| | Schem, Christian [VerfasserIn] |
|---|
| | Stickeler, Elmar [VerfasserIn] |
|---|
| | Fasching, Peter Andreas [VerfasserIn] |
|---|
| | Budczies, Jan [VerfasserIn] |
|---|
| | Felder, Bärbel [VerfasserIn] |
|---|
| | Nekljudova, Valentina [VerfasserIn] |
|---|
| | Holtschmidt, Johannes [VerfasserIn] |
|---|
| | Untch, Michael [VerfasserIn] |
|---|
| | Denkert, Carsten [VerfasserIn] |
|---|
| | Loibl, Sibylle [VerfasserIn] |
|---|
| Titel: | An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in patients with breast cancer from four prospective clinical trials |
|---|
| Verf.angabe: | Paul Jank, Thomas Karn, Marion van Mackelenbergh, Judith Lindner, Denise Treue, Jens Huober, Knut Engels, Christine Solbach, Kurt Diebold, Frederik Marmé, Volkmar Müller, Andreas Schneeweiss, Hans-Peter Sinn, Tanja Fehm, Christian Schem, Elmar Stickeler, Peter Fasching, Jan Budczies, Bärbel Felder, Valentina Nekljudova, Johannes Holtschmidt, Michael Untch, Carsten Denkert, and Sibylle Loibl |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 1 September 2024 |
|---|
| Umfang: | 13 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online veröffentlicht: 3. September 2024 ; Gesehen am 12.11.2024 |
|---|
| Titel Quelle: | Enthalten in: Clinical cancer research |
|---|
| Ort Quelle: | Philadelphia, Pa. [u.a.] : AACR, 1995 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 30(2024), 17, Seite 3868-3880 |
|---|
| ISSN Quelle: | 1557-3265 |
|---|
| Abstract: | The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations in PIK3CA are relevant for therapy resistance in HER2-positive (HER2pos) breast cancer. Mutations in exons 9 or 20 may have different impacts on response to neoadjuvant chemotherapy-based treatment regimens.We investigated PIK3CA mutations in 1,691 patients with early breast cancer who were randomized into four neoadjuvant multicenter trials: GeparQuattro (NCT00288002), GeparQuinto (NCT00567554), GeparSixto (NCT01426880), and GeparSepto (NCT01583426). The role of different PIK3CA exons and hotspots for pathologic complete response (pCR) following neoadjuvant chemotherapy (NACT) and patient survival were evaluated for distinct molecular subgroups and anti-HER2 treatment procedures.A total of 302 patients (17.9%) of the full cohort of 1,691 patients had a tumor with a PIK3CA mutation, with a different prevalence in molecular subgroups: luminal/HER2-negative (HER2neg) 95 of 404 (23.5%), HER2pos 170 of 819 (20.8%), and triple-negative breast cancer 37 of 468 patients (7.9%). We identified the mutations in PIK3CA exon 20 to be linked with worse response to anti-HER2 treatment (OR = 0.507; 95% confidence interval, 0.320-0.802; P = 0.004), especially in hormone receptor-positive HER2-positive breast cancer (OR = 0.445; 95% confidence interval, 0.237-0.837; P = 0.012). In contrast, exon 9 hotspot mutations p.E452K and p.E545K revealed no noteworthy differences in response therapy. Luminal/HER2neg patients show a trend to have worse treatment response when PIK3CA was mutated. Interestingly, patients with residual disease following neoadjuvant treatment had better survival rates when PIK3CA was mutated.The PIK3CA hotspot mutation p.H1047R is associated with worse pCR rates following NACT in HER2pos breast cancer, whereas hotspot mutations in exon 9 seem to have less impact. |
|---|
| DOI: | doi:10.1158/1078-0432.CCR-24-0459 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1158/1078-0432.CCR-24-0459 |
|---|
| | Volltext: https://aacrjournals.org/clincancerres/article/30/17/3868/747287/An-Analysis-of-PIK3CA-Hotspot-Mutations-and |
|---|
| | DOI: https://doi.org/10.1158/1078-0432.CCR-24-0459 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 190826554X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬An¬ analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in patients with breast cancer from four prospective clinical trials / Jank, Paul [VerfasserIn]; 1 September 2024 (Online-Ressource)
